Search Results - "Davies, Richard Y."

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome by Correa, Simon, Morrow, David A, Braunwald, Eugene, Davies, Richard Y, Goodrich, Erica L, Murphy, Sabina A, Cannon, Christopher P, O'Donoghue, Michelle L

“…Background Cystatin C (Cys-C) is a marker of renal function that has shown prognostic value for cardiovascular risk stratification across different patient…”
Get full text

Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease by Wallentin, Lars, Held, Claes, Armstrong, Paul W., Cannon, Christopher P., Davies, Richard Y., Granger, Christopher B., Hagström, Emil, Harrington, Robert A., Hochman, Judith S., Koenig, Wolfgang, Krug‐Gourley, Sue, Mohler, Emile R., Siegbahn, Agneta, Tarka, Elizabeth, Steg, Philippe Gabriel, Stewart, Ralph A. H., Weiss, Robert, Östlund, Ollie, White, Harvey D., Budaj, Andrzej, Ardissino, Diego, Avezum, Alvaro, Aylward, Philip E., Bryce, Alfonso, Chen, Hong, Chen, Ming‐Fong, Corbalan, Ramon, Dalby, Anthony J., Danchin, Nicolas, De Winter, Robbert J., Denchev, Stefan, Diaz, Rafael, Elisaf, Moses, Flather, Marcus D., Goudev, Assen R., Grinfeld, Liliana, Husted, Steen, Kim, Hyo‐Soo, Linhart, Ales, Lonn, Eva, López‐Sendón, José, Manolis, Athanasios J., Nicolau, José C., Pais, Prem, Parkhomenko, Alexander, Pedersen, Terje R., Pella, Daniel, Ramos‐Corrales, Marco A., Ruda, Mikhail, Sereg, Mátyás, Siddique, Saulat, Sinnaeve, Peter, Sritara, Piyamitr, Swart, Henk P., Sy, Rody G., Teramoto, Tamio, Tse, Hung‐Fat, Weaver, W. Douglas, Viigimaa, Margus, Vinereanu, Dragos, Zhu, Junren

“…Background We evaluated lipoprotein‐associated phospholipase A2 (Lp‐PLA2) activity in patients with stable coronary heart disease before and during treatment…”
Get full text

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease by WHITE, Harvey D, HELD, Claes, ARMSTRONG, Paul W, AVEZUM, Alvaro, AYLWARD, Philip E, BRYCE, Alfonso, HONG CHEN, CHEN, Ming-Fong, CORBALAN, Ramon, DALBY, Anthony J, DANCHIN, Nicolas, DE WINTER, Robbert J, STEWART, Ralph, DENCHEV, Stefan, DIAZ, Rafael, ELISAF, Moses, FLATHER, Marcus D, GOUDEV, Assen R, GRANGER, Christopher B, GRINFELD, Liliana, HOCHMAN, Judith S, HUSTED, Steen, KIM, Hyo-Soo, TARKA, Elizabeth, WOLFGANG KOENIG, LINHART, Ales, LONN, Eva, LOPEZ-SENDON, José, MANOLIS, Athanasios J, MOHLER, Emile R, NICOLAU, José C, PAIS, Prem, PARKHOMENKO, Alexander, PEDERSEN, Terje R, BROWN, Rebekkah, PELLA, Daniel, RAMOS-CORRALES, Marco A, RUDA, Mikhail, SEREG, Mátyás, SIDDIQUE, Saulat, SINNAEVE, Peter, SMITH, Peter, SRITARA, Piyamitr, SWART, Henk P, SY, Rody G, DAVIES, Richard Y, TERAMOTO, Tamio, TSE, Hung-Fat, WATSON, David, WEAVER, W. Douglas, WEISS, Robert, VIIGIMAA, Margus, VINEREANU, Dragos, JUNREN ZHU, CANNON, Christopher P, BUDAJ, Andrzej, HARRINGTON, Robert A, STEG, P. Gabriel, ARDISSINO, Diego

“…Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease…”
Get full text

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial by O’Donoghue, Michelle L, Braunwald, Eugene, White, Harvey D, Steen, Dylan P, Lukas, Mary Ann, Tarka, Elizabeth, Steg, P. Gabriel, Hochman, Judith S, Bode, Christoph, Maggioni, Aldo P, Im, KyungAh, Shannon, Jennifer B, Davies, Richard Y, Murphy, Sabina A, Crugnale, Sharon E, Wiviott, Stephen D, Bonaca, Marc P, Watson, David F, Weaver, W. Douglas, Serruys, Patrick W, Cannon, Christopher P

“…IMPORTANCE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation…”
Get full text

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial by O’Donoghue, Michelle L, Glaser, Ruchira, Cavender, Matthew A, Aylward, Philip E, Bonaca, Marc P, Budaj, Andrzej, Davies, Richard Y, Dellborg, Mikael, Fox, Keith A. A, Gutierrez, Jorge Antonio T, Hamm, Christian, Kiss, Robert G, Kovar, František, Kuder, Julia F, Im, Kyung Ah, Lepore, John J, Lopez-Sendon, Jose L, Ophuis, Ton Oude, Parkhomenko, Alexandr, Shannon, Jennifer B, Spinar, Jindrich, Tanguay, Jean-Francois, Ruda, Mikhail, Steg, P. Gabriel, Theroux, Pierre, Wiviott, Stephen D, Laws, Ian, Sabatine, Marc S, Morrow, David A

“…IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive…”
Get full text

Once-Monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women with Postmenopausal Osteoporosis by Lewiecki, E. Michael, Keaveny, Tony M., Kopperdahl, David L., Genant, Harry K., Engelke, Klaus, Fuerst, Thomas, Kivitz, Alan, Davies, Richard Y., Fitzpatrick, Lorraine A.

“…Context: Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone…”
Get full text

Rates of change and sensitivity to change in cartilage morphology in healthy knees and in knees with mild, moderate, and end‐stage radiographic osteoarthritis: Results from 831 participants from the osteoarthritis initiative by Eckstein, Felix, Nevitt, Michael, Gimona, Alberto, Picha, Kristen, Lee, Jennifer H., Davies, Richard Y., Dreher, Donatus, Benichou, Olivier, Le Graverand, Marie‐Pierre Hellio, Hudelmaier, Martin, Maschek, Susanne, Wirth, Wolfgang

“…Objective To study the longitudinal rate of (and sensitivity to) change of knee cartilage thickness across defined stages of radiographic osteoarthritis (OA),…”
Get full text

Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis by Engelke, Klaus, Fuerst, Thomas, Dasic, Gorana, Davies, Richard Y, Genant, Harry K

“…Abstract In the published placebo-controlled Ibandronate Quality (IQ) study, 12 months of once-monthly oral ibandronate increased femoral and vertebral…”
Get full text

Lipoprotein-Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease by Wallentin, Lars, Held, Claes, Armstrong, Paul W., Cannon, Christopher P., Davies, Richard Y., Granger, Christopher B., Hagström, Emil, Harrington, Robert A., Hochman, Judith S., Koenig, Wolfgang, Krug-Gourley, Sue, Mohler, Emile R., III, Siegbahn, Agneta, Tarka, Elizabeth, Steg, Philippe Gabriel, Stewart, Ralph A. H., Weiss, Robert, östlund, Ollie, White, Harvey D.

“…Background - We evaluated lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in patients with stable coronary heart disease before and during…”
Get full text

MRI-based extended ordered values more efficiently differentiate cartilage loss in knees with and without joint space narrowing than region-specific approaches using MRI or radiography – data from the OA initiative by Wirth, W, Buck, R, Nevitt, M, Le Graverand, M.P.H, Benichou, O, Dreher, D, Davies, R.Y, Lee, J.H, Picha, K, Gimona, A, Maschek, S, Hudelmaier, M, Eckstein, F

“…Summary Objective The sensitivity to change of quantitative analysis of cartilage in knee osteoarthritis using magnetic resonance imaging (MRI) is compromised…”
Get full text

Sensitivity to change of cartilage morphometry using coronal FLASH, sagittal DESS, and coronal MPR DESS protocols – comparative data from the osteoarthritis initiative (OAI) by Wirth, W, Nevitt, M, Hellio Le Graverand, M.-P, Benichou, O, Dreher, D, Davies, R.Y, Lee, J, Picha, K, Gimona, A, Maschek, S, Hudelmaier, M, Eckstein, F

“…Summary Objective The Osteoarthritis Initiative (OAI) is targeted at identifying sensitive biomarkers and risk factors of symptomatic knee osteoarthritis (OA)…”
Get full text

Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure by White, Harvey D., Held, Claes, Stewart, Ralph, Tarka, Elizabeth, Brown, Rebekkah, Davies, Richard Y., Budaj, Andrzej, Harrington, Robert A., Steg, P. Gabriel, Ardis-Sino, Diego, Armstrong, Paul W., Avezum, Alvaro, Aylward, Philip E., Bryce, Alfonso, Chen, Hong, Chen, Ming-Fong, Corbalan, Ramon, Dalby, Anthony J., Danchin, Nicolas, De Winter, Robbert J., Denchev, Stefan, Diaz, Rafael, Elisaf, Moses, Flather, Marcus D., Goudev, Assen R., Granger, Christopher B., Grinfeld, Liliana, Hochman, Judith S., Husted, Steen, Kim, Hyo-Soo, Koenig, Wolfgang, Linhart, Ales, Lonn, Eva, Lopez-Sendon, Jose, Manolis, Athanasios J., Mohler, Emile R., III, Nicolau, Jose C., Pais, Prem, Parkhomenko, Alexander, Pedersen, Terje R., Pella, Daniel, Ramos-Corrales, Marco A., Ruda, Mikhail, Sereg, Mtys, Siddique, Saulat, Sinnaeve, Peter, Smith, Peter, Sritara, Piyamitr, Swart, Henk P., Sy, Rody G., Teramoto, Tamio, Tse, Hung-Fat, Watson, David, Weaver, W. Douglas, Weiss, Robert, Viigimaa, Margus, Vinereanu, Dragos, Zhu, Junren, Cannon, Christopher P., Wallentin, Lars

“…Background: Elevated lipoprotein-associated phospholipase A(2) activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma…”
Get full text

Comparison of One-Year Versus Two-year Change in Regional Cartilage Thickness in Osteoarthritis Results from 346 Participants From the Osteoarthritis Initiative by Wirth, Wolfgang, Larroque, Sylvain, Davies, Richard Y, Nevitt, Michel, Gimona, Alberto, Baribaud, Frédéric, Lee, Jennifer H, Benichou, Olivier, Wyman, Bradley T, Hudelmaier, Martin, Maschek, Susanne, Eckstein, Felix

Get full text

Lipoprotein‐Associated Phospholipase A 2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease by Wallentin, Lars, Held, Claes, Armstrong, Paul W., Cannon, Christopher P., Davies, Richard Y., Granger, Christopher B., Hagström, Emil, Harrington, Robert A., Hochman, Judith S., Koenig, Wolfgang, Krug‐Gourley, Sue, Mohler, Emile R., Siegbahn, Agneta, Tarka, Elizabeth, Steg, Philippe Gabriel, Stewart, Ralph A. H., Weiss, Robert, Östlund, Ollie, White, Harvey D., Budaj, Andrzej, Ardissino, Diego, Avezum, Alvaro, Aylward, Philip E., Bryce, Alfonso, Chen, Hong, Chen, Ming‐Fong, Corbalan, Ramon, Dalby, Anthony J., Danchin, Nicolas, De Winter, Robbert J., Denchev, Stefan, Diaz, Rafael, Elisaf, Moses, Flather, Marcus D., Goudev, Assen R., Grinfeld, Liliana, Husted, Steen, Kim, Hyo‐Soo, Linhart, Ales, Lonn, Eva, López‐Sendón, José, Manolis, Athanasios J., Nicolau, José C., Pais, Prem, Parkhomenko, Alexander, Pedersen, Terje R., Pella, Daniel, Ramos‐Corrales, Marco A., Ruda, Mikhail, Sereg, Mátyás, Siddique, Saulat, Sinnaeve, Peter, Sritara, Piyamitr, Swart, Henk P., Sy, Rody G., Teramoto, Tamio, Tse, Hung‐Fat, Weaver, W. Douglas, Viigimaa, Margus, Vinereanu, Dragos, Zhu, Junren

“…Background We evaluated lipoprotein‐associated phospholipase A 2 (Lp‐ PLA 2 ) activity in patients with stable coronary heart disease before and during…”
Get full text